Efficiency of drug delivery enhanced by acoustic pressure during blood–brain barrier disruption induced by focused ultrasound

Feng-Yi Yang
Pei-Yi Lee
Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan

Purpose: We evaluated the delivery efficiency of intravenously injected large molecular agents, before and after disruption of the blood–brain barrier (BBB-D), induced by focused ultrasound (FUS) using various acoustic parameters.

Materials and methods: Male Sprague-Dawley rats were injected intravenously with Evans blue (EB) before or after BBB-D induction by pulsed FUS. We used a 1.0 MHz pulsed FUS with four acoustic power settings and an ultrasound contrast agent (UCA) at four different doses to induce BBB-D resulting from cavitation. The permeability of the BBB was assessed quantitatively based on the extravasation of EB. Contrast enhanced magnetic resonance imaging (MRI) was used to monitor the gadolinium deposition associated with FUS. Histological analysis was performed to examine tissue damage.

Results: The accumulation of EB in rat brain was found to be dependent on acoustic power and UCA dosage, regardless of whether EB administration occurred before or after FUS-induced BBB-D. Administration of EB followed by sonication resulted in greater EB extravasation than that for rats subjected to sonication prior to EB injection. To reduce tissue damage, EB extravasation was enhanced by first administering EB by intravenous injection, followed by sonication at reduced acoustic power or UCA dosage. The normalized signal intensity change in rat brains that received the same dose of UCA and sonicated after gadolinium injection was significantly greater than in rats undergoing sonication followed by gadolinium administration. Moreover, contrast enhanced MRI showed a more precise distribution of gadolinium in the brain when gadolinium was administered before sonication.

Conclusion: We demonstrated that a compound administered prior to sonication treatment promotes extravasation of the sonicated region. Thus, it is possible to optimize ultrasound parameters for lower sonication and reduced UCA doses, to induce BBB-D while minimizing damage to normal brain tissue.

Keywords: drug administration, delivery efficiency, blood–brain barrier, focused ultrasound, permeability

Introduction
Therapeutic agents are often difficult to administer to the brain because the blood–brain barrier (BBB) has low permeability to ionized water-soluble molecules with a molecular mass greater than 180 Da.1 Many approaches have been developed to enhance drug delivery to the brain, but these may involve increasing the dosage of drugs throughout the brain or may increase the risk of sustaining neurological damage. Recent experiments have shown that local and reversible BBB disruption (BBB-D) can be accomplished noninvasively using pulsed focused ultrasound (FUS)
in the presence of microbubbles; pulsed FUS produces mechanical effects such as radiation forces, microstreaming, and cavitation that enhance the permeability of the BBB in a nondestructive manner. The degree of BBB-D is dependent on various ultrasound parameters including acoustic power, dosage of ultrasound contrast agent (UCA), and the number of sonications that are carried out.2

Many chemotherapy treatments are ineffective because drugs fail to reach therapeutic levels in the target brain tumor due to limited permeability of the BBB.3 Previous works have reported that first-line high-dose chemotherapy provides a potential survival benefit compared to historical control patients receiving standard-dose therapies.4,5 Traditional high-dose chemotherapy can improve treatment efficacy, but its clinical application is often limited by systemic toxicity. Therefore, it is important to find methods to deliver sufficient quantities of drugs to the target region, without increasing systemic dosage. We previously reported that the concentration of Evans blue (EB) in tumors and the tumor-to-normal brain ratio of EB in the brain are elevated after BBB-D induction by pulsed FUS. Moreover, repeated pulsed FUS exposure further increases the efficiency of EB delivery to the brain.6–9

One study demonstrated that FUS exposure following EB injection provides nearly a threefold increase in the amount of EB extravasated in sonicated hepatocellular carcinoma compared with that from carcinoma sonicated prior to EB administration.10 Interestingly, the enhanced efficacy of FUS was absent when EB was administered after sonication. This result is consistent with a previous report of cardiac protein delivery.11 Fluid microjets are responsible for the increased capillary permeability and transient nanopores observed in cell membranes following FUS destruction of microbubbles.12,13 These reports suggest that the drug administration procedure must be considered when applying FUS treatment with therapeutic agents. Furthermore, FUS has been used to enhance local drug delivery and increase the antitumor effects in the treatment of brain tumors.14–16

In this study, we evaluated the delivery efficiency of EB administration before and after BBB-D induced by FUS. In addition, we studied the effects of various ultrasound parameters on the efficacy of extravasation. Our aim was to optimize FUS mediated drug delivery to the brain, to minimize tissue damage.

Materials and methods

Experimental animals
Male Sprague–Dawley rats weighing from 280 to 350 g were used in this study. All experiments were performed according to the approved protocols of our institutional animal care and use committee. Rats were anesthetized with chloral hydrate by intraperitoneal injection (400 mg/kg), and body temperature was maintained at 37°C using a heating pad. The top of the cranium was shaved and the scalp overlaying the skull was incised to facilitate use of the bregma as an anatomic landmark for targeting. The rat heads were mounted on stereotaxic apparatus (Stoelting, Wood Dale, IL) with the nose bar positioned 3.3 mm below the interaural line. Ultrasound transmission gel (Pharmaceutical Innovations, Newark, NJ) was used to cover the area between the transducer and the skull to maximize ultrasound transmission. In this study, three rats were employed in each group except the magnetic resonance imaging (MRI) analysis group which used four rats.

Pulsed ultrasound equipment
FUS exposure was provided by a 1 MHz focused transducer (A392S; Panametrics, Waltham, MA) with a diameter of 38 mm and radius of curvature of 63.5 mm. The half-maximum of the pressure amplitude at the focal zone was 3 mm in diameter and 26 mm in length. The acoustic power output was measured with a radiation force balance (RFB-2000; Onda, Sunnyvale, CA). The transducer was mounted on a removable cone filled with deionized and degassed water, and a polyurethane membrane capped its tip; the center of the focal spot was approximately 5.7 mm from the cone tip. FUS was precisely targeted using stereotaxic apparatus that utilized the bregma as the anatomical target. Pulsed FUS was applied with 50 millisecond burst lengths at a 5% duty cycle and repetition frequency of 1 Hz. Pulsed FUS was delivered to the right hemisphere at a site 3.5 mm posterior and 2.5 mm lateral to the bregma, and 5.7 mm below the skull surface. UCA (SonoVue; Bracco International, Amsterdam, Netherlands), comprising phospholipid-coated microbubbles with mean diameter of 2.5 µm at a concentration of between 1 × 108 and 5 × 108 bubbles/mL, was intravenously administered via the femoral vein approximately 15 seconds before sonication.

Experimental protocols
To evaluate the degree of BBB permeability, we compared two procedures for EB (100 mg/kg) injection into the rats’ femoral vein (Figure 1). The animals received EB injection about 5 minutes before or immediately after FUS exposure. In the first set of experiments, rats were sonicated with FUS in the presence of microbubbles for sonication durations of 0 to 60 seconds. In the experiments that followed, we...
quantiﬁed EB accumulation in rat brains after sonication for 60 seconds. In the second set of experiments, rats were injected with UCA at 300 µL/kg approximately 15 seconds prior to FUS exposure at various acoustic powers (0, 1.43, 2.86, and 4.29 W). In the third set of experiments, rats were exposed to a sonication power of 2.86 W in the presence of microbubbles at four doses (0, 150, 300, and 450 µL/kg). In the ﬁnal experiment, rats received an injection of gadolinium about 5 minutes before or immediately after FUS exposure, for MRI analysis.

Quantification of EB accumulation
The permeability of the BBB can be quantiﬁed based on the extravasation of EB (Sigma, St Louis, MO), which acts as a marker of albumin extravasation.9,17,18 EB-treated rats were sacriﬁced approximately 4 hours after sonication. The rats were perfused with saline via the left ventricle, until a colorless perfusion ﬂuid appeared from the right atrium. After perfusion and brain removal, the brain was sectioned into three slices from 0 mm to 6 mm posterior to the bregma, and these were mounted on glass slides. The coronal sections were then divided into right and left hemispheres before measuring the amount of EB extravasated. The rats’ nonsonicated left hemispheres acted as the control. Samples were weighed and then soaked in 50% trichloroacetic acid solution. After homogenization and centrifugation, the extracted dye was diluted with ethanol (1:3), and the amount of EB present determined using a spectrophotometer (PowerWave 340; BioTek, Winooski, VT) at 620 nm.19 The EB present in the tissue samples was quantiﬁed using a linear regression standard curve derived from seven concentrations of the dye; the amount of dye was expressed in absorbance per gram of tissue.

MRI
Contrast enhancement of the T1-weighted MRI was used to monitor the BBB-D permeability. Following FUS sonication, MRI was performed using a 3T MRI system (TRIO 3-T MRI; Siemens AG MAGNETOM, Erlangen, Germany). Rats were anesthetized with 1.5% isoflurane mixed with oxygen gas, and maintained at 1% isoflurane throughout the imaging procedure. A small loop coil (Loop Flex Coil; Siemens) approximately 4 cm in diameter was used for radio frequency reception. A multislice spin echo sequence was performed to obtain 20 slices of the T1-weighted MRI covering the whole brain to image the
BBB-D (repetition time/echo time = 435/12 milliseconds; matrix = 154 × 256; section thickness = 1.5 mm). The imaging plane was located across the center of the focal zone, perpendicular to the axis of ultrasound beam. The MRI contrast agent gadolinium (Omniscan; GE Healthcare, Cork, Ireland) was injected intravenously (1 mmol/kg) about 5 minutes before or immediately after sonication. MRI contrast enhancement was analyzed 60 minutes after gadolinium administration. Contour maps describing the spatial distribution of contrast enhancement were quantified for the BBB-D. Regions of contrast enhancement greater than 1.5, 3.0, 4.5, and 6.0 standard deviations of the averaged spatial normal brain regions were color-coded to facilitate identification.

Histological examination
Rats were sacrificed approximately 24 hours after sonication for histological assessment. Rats were perfused with saline and 10% neutral buffered formalin. The brains were removed and embedded in paraffin, and then serially sectioned into 30 μm thick slices. The slices were stained with hematoxylin and eosin (H&E; Thermo-Scientific, Waltham, MA) and TUNEL staining (DeadEnd Colorimetric TUNEL system, G7130; Promega, Madison, WI). The photomicrographs of 5 μm thickness for the H&E and TUNEL-stained tissues were obtained using a Mirax Scan digital microscope slide scanner (Mirax 3D Histech; Carl Zeiss, Rochester, NY) with a Plan-Apochromatic 20/0.8 objective lens. The total area of each tissue section and the areas showing apoptosis were measured using the Image-Pro Plus software package (Media Cybernetics, Silver Spring, MD) in a blinded manner. The percentage of the tissue exhibiting apoptosis was calculated as follows: (area of the tissue containing apoptotic cells/total area of the tissue sections measured) × 100. In total, six tissue sections from each brain were analyzed.

Statistical analysis
All values are shown as means ± standard error of mean (SEM). Statistical analysis was performed using the unpaired Student's t-test. Statistical significance was defined as P value ≤0.05.

Results
Effect of sonication duration on BBB-D
Figure 2 shows that BBB permeability was dependent on the duration of sonication, whether performed before or after EB administration. Moreover, it shows a significant increase in EB accumulation for the group of rats that received EB injection before sonication, at every time point, compared to the EB accumulation in rats that received EB after sonication. Both groups showed an absorption phase from 0 to 40 seconds, and then exhibited a plateau in EB concentration between 40 and 60 seconds.

Figure 2 The amount of EB extravasation in brain tissue was assessed as a function of sonication time after FUS exposure following (solid circle), and followed by (open circle), EB injection at UCA dosage 150 μL/kg.

Note: *Significant difference between the two groups for the same specific sonication duration at a sonication power of 2.86 W (P < 0.05).

Abbreviations: EB, Evans blue; FUS, focused ultrasound; UCA, ultrasound contrast agent.
Procedure of EB administration for doxorubicin accumulation

Figure 3 shows the mean extravasation of EB per unit mass of brain tissue from the sonicated site for four sonication powers, for the same dose of UCA. The degree of EB extravasation increased with acoustic power. Additionally, the amount of EB extravasation was greater in the group injected before sonication than it was in the group receiving EB after sonication; this difference was particularly evident for the lowest sonication power of 1.43 W ($P < 0.05$). Figure 4 shows that the amount of EB extravasated from sonicated brains increased with increasing UCA dose from 0 to 450 µL/kg at 2.86 W sonication power. Moreover, these concentrations were greater in the group that received EB injection before sonication than they were in the group that received EB administration after sonication, particularly for the highest UCA dose of 450 µL/kg ($P < 0.01$). Importantly, however, the EB extravasation was significantly greater in brains with the EB injection followed by sonication for UCA at 300 µL/kg than it was for brains with EB administration following sonication for UCA at 450 µL/kg ($P < 0.05$). In contrast to EB concentration values for the sonicated brains, only insignificant differences were found for the values of control brains at the various acoustic powers and UCA doses.

MRI analysis

Figure 5A and C shows MRIs depicting the spatial distribution of gadolinium deposition in rats receiving administration of gadolinium followed by sonication at a power of 2.86 W, for UCA doses of 300 and 450 µL/kg. The intensity of the contrast enhancement was greater after injecting UCA at 450 µL/kg than it was for UCA at 300 µL/kg. Figure 5B shows the distribution of gadolinium injection following sonication at an acoustic power of 2.86 W, for the UCA dose of 450 µL/kg. Interestingly, there was less intensity in the contrast enhancement after injecting UCA at 450 µL/kg (Figure 5B) than the intensity resulting from 300 µL/kg UCA (Figure 5A). The contour maps in this figure show the extent of gadolinium deposition; there is clearly a better focused gadolinium distribution (red and blue regions) in brains receiving sonication following gadolinium administration in Figure 5A and C compared to brains that received sonication followed by gadolinium injection (Figure 5B). Following gadolinium administration, the normalized signal intensity change in focal volume was significantly greater after injecting UCA at 450 µL/kg than it was at 300 µL/kg for the same sonication power (Figure 6). The normalized signal intensity change in rat brains that received a UCA dose of 450 µL/kg and sonicated after gadolinium injection was significantly greater than in rats undergoing sonication followed by gadolinium administration. It was also found that the normalized signal intensity change in the rats that received UCA at 300 µL/kg and sonication following gadolinium administration was significantly greater than in rats that received a UCA dose of 450 µL/kg with sonication followed by gadolinium administration.

![Figure 3](image-url)  
**Figure 3** Relationship between EB extravasation and sonication power after microbubble and FUS treatment, following and followed by, EB injection at the UCA dose of 300 µL/kg.  
**Notes:** *Significant difference compared to the contralateral nonsonicated hemisphere; **Significant difference between two sonicated groups. (* and **, $P < 0.05$).  
**Abbreviations:** EB, Evans blue; FUS, focused ultrasound; MB, microbubble; UCA, ultrasound contrast agent.
Figure 4 Relationship between EB extravasation and UCA dosage after FUS treatment, following and followed by, EB injection at a sonication power of 2.86 W.

Notes: *Significant difference compared with the contralateral nonsonicated hemisphere; #Significant difference between two sonicated groups. (* and #, P < 0.05; ##, P < 0.01).

Abbreviations: EB, Evans blue; FUS, focused ultrasound; MB, microbubble; UCA, ultrasound contrast agent.

Figure 5 Distribution of BBB disruption for gadolinium administration (A) followed by sonication at 2.86 W with UCA doses of 300 µL/kg and (B) following sonication at 2.86 W with the UCA dose of 450 µL/kg and (C) 450 µL/kg.

Notes: The right hemisphere was treated with FUS, and the left was the control. Regions with contrast enhancement are shown as >1.5 (green), >3.0 (yellow), >4.5 (blue), and >6.0 (red) standard deviations above the average MRI signal intensity of the contralateral normal tissue in the left hemisphere are shown.

Abbreviations: BBB, blood–brain barrier; FUS, focused ultrasound; MRI, magnetic resonance imaging; UCA, ultrasound contrast agent.

Figure 6 Normalized signal intensity change of the contrast-enhanced T1 weighted MRIs in sonicated brains derived from Figure 5.

Note: **P < 0.01.

Abbreviations: FUS, focused ultrasound; Gd, gadolinium; MRI, magnetic resonance imaging; SI, signal intensity.
**Histological evaluation**

Figure 7 shows representative H&E-stained sections for UCA treatments at 300 and 450 µL/kg at sonication power of 2.86 W. The corresponding TUNEL-stained sections were prepared for histopathologic examination and apoptotic evaluation (Figure 8). Red blood cells were present in sonicated brain tissue in and around the focal region, and were more severe for the higher dose (450 µL/kg) samples. This observation is consistent with the finding that more apoptotic cells were present in sonicated UCA 450 µL/kg samples than they were in UCA 300 µL/kg samples. Figure 9 indicates that there were significant differences between these two groups.

**Discussion**

This study demonstrated that drug administration strategy has an impact on the efficacy of FUS induced BBB-D, and on the resulting efficiency of drug delivery. Interactions between sonication and microbubbles can further promote extravasation in sonicated regions of the brain. EB extravasation in the group of rats injected with EB before sonication was significantly greater than in the group injected with EB after sonication at every time point (Figure 2). These results indicate that a phenomenon other than diffusion, such as cavitation, microstreaming, and oscillation, increases extravasation when EB is injected prior to sonication. This is in agreement with a previous report,\(^\text{10}\), where significantly increased extravasation occurred in hepatomas that were sonicated after administration of EB, but not in hepatomas sonicated before EB injection.

Our results indicate that the promoted extravasation by EB injection before sonication was most significant at the lowest acoustic power of 1.43 W and at the highest UCA dose of 450 µL/kg. In particular, EB extravasation for EB injection before sonication for the UCA 300 µL/kg group was significantly greater than for EB injection after sonication for the UCA 450 µL/kg group. The implication of this finding is that sonication after drug administration is associated with further increases in drug accumulation even though UCA is administered at a lower dose. A greater UCA dosage provides more microbubbles in blood vessels to serve as nuclei for cavitation, thus augmenting extravasation.\(^\text{18,20}\) However, increased numbers of microbubbles can induce extravasation of erythrocytes and increase the numbers

---

**Figure 7** Hematoxylin and eosin staining of transverse brain sections sonicated at 2.86 W with UCA doses of (A–C) 300 µL/kg and (D–F) 450 µL/kg.

**Notes:** The affected brain structures include the hypothalamus, thalamus, and hippocampus. Local displacement and increased extravasation of red blood cells were more obvious in specimens treated at the greater UCA dosage of 450 µL/kg than in specimens treated with UCA doses of 300 µL/kg.

**Abbreviation:** UCA, ultrasound contrast agent.
of apoptotic cells. This might explain why the apoptotic cells were mainly localized to the microvascular walls, with only a few apoptotic cells observed outside the focal regions. Therefore, it is essential to optimize ultrasound parameters for lower sonication powers and reduced UCA doses, to induce BBB-D while minimizing damage to normal brain tissue.

The exact mechanism of BBB-D induction by FUS remains unclear. Several studies report that the BBB-D is probably the result of mechanical effects associated

Figure 8 Examples of histological observations of TUNEL-stained sections treated with UCA doses of (A–C) 300 µL/kg and (D–F) 450 µL/kg sonicated at 2.86 W.

Note: Many cells appear to be undergoing apoptosis in the sonicated brains.

Abbreviation: UCA, ultrasound contrast agent.

Figure 9 Percentage of apoptotic cells counted in microscopic fields (total area: 4000 × 9000 µm) of the sonicated brains during histological observations of TUNEL-stained sections.

Note: *p < 0.05.
with interactions between ultrasound and microbubbles. Microbubbles have potential therapeutic application in causing tissue damage and increasing blood vessel permeability in muscle.\textsuperscript{21,22} Furthermore, our previous works found that higher doses of UCA, or increased FUS sonication power produced longer lasting disruption of the BBB.\textsuperscript{7,9} Safety may become a concern if BBB-D is prolonged, because an impermeable BBB is vital to maintaining normal brain physiology. Thus, the procedure for drug administration is another potentially important factor in enhancing drug delivery by FUS under mild sonication conditions to minimize adverse effects. In addition to assessing histology, we also monitored patterns of contrast enhancement. The MRIs shown in Figure 5 are contour maps revealing that gadolinium deposition in rats injected with gadolinium prior to sonication is more concentrated in the focal region than the gadolinium concentration that occurs when gadolinium injection follows sonication. One explanation could be that cavitation activity enhances the accumulation of gadolinium in the focal region when gadolinium is administered prior to sonication.

In conclusion, this study demonstrates that cavitation induced by FUS in the presence of microbubbles significantly increases the delivery efficiency of EB to the brain, if sonication is carried out after EB administration. Our findings will aid the development of an optimal procedure for FUS assisted drug delivery to the brain while minimizing brain tissue damage.

**Acknowledgments**

This study was supported by grants from the National Science Council of Taiwan (no NSC 100-2321-B-010-010 and NSC 99-2321-B-010-017), Department of Health of Taiwan (DOH101-TD-PB-111-TM012 and DOH101-TD-C-111-007), Veterans General Hospitals University System of Taiwan Joint Research Program (#VGHUST100-G1-3-3), Yen Tjing Ling Medical Foundation (grant CI-100-17), and Cheng Hsin General Hospital Foundation (no 100F117CY25 and 101F195CY18).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. *Neurosurgery*. 1998;42:1083–1099; discussion 1099–1100.
2. McDannold N, Vykhodtseva N, Hynynen K. Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. *Ultrasound Med Biol*. 2008;34:930–937.
3. Cordon-Cardo C, O’Brien JP, Casals D, et al. Multidrug-resistance gene (p-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. *Proc Natl Acad Sci U S A*. 1989;86:695–698.
4. Motzer RJ, Mazumdar M, Gulati SC, et al. Phase ii trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. *J Natl Cancer Inst*. 1993;85:1826–1835.
5. Motzer RJ, Mazumdar M, Bajorin DF, Bodi GI, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. *J Clin Oncol*. 1997;15:2546–2552.
6. Yang FY, Wang HE, Lin GL, et al. Microspect/cct-based pharmacokinetic analysis of 99m-te-diethylenetriaminepentacetic acid in rats with blood-brain barrier disruption induced by focused ultrasound. *J Nucl Med*. 2011;52:478–484.
7. Yang FY, Horng SC, Lin YS, Kao YH. Association between contrast-enhanced mr images and blood-brain barrier disruption following transcranial focused ultrasound. *J Magn Reson Imaging*. 2010;32:593–599.
8. Yang FY, Lin YS, Kang KH, Chao TK. Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation. *J Control Release*. 2011;150:111–116.
9. Yang FY, Liu SH, Ho FM, Chang CH. Effect of ultrasound contrast agent dose on the duration of focused-ultrasound-induced blood-brain barrier disruption. *J Acoust Soc Am*. 2009;126:3344–3349.
10. Bekeredjian R, Kroll R, Fein E, et al. Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. *Ultrasound Med Biol*. 2007;33:1592–1598.
11. Bekeredjian R, Chen S, Grayburn PA, Shoehet RV. Augmentation of cardiac protein delivery using ultrasound targeted microbubble destruction. *Ultrasound Med Biol*. 2003;31:687–691.
12. Brujan EA. The role of cavitation microjets in the therapeutic applications of ultrasound. *Ultrasound Med Biol*. 2004;30:381–387.
13. Miller DL, Quddus J. Sonoporation of monolayer cells by diagnostic ultrasound activation of contrast-agent gas bodies. *Ultrasound Med Biol*. 2000;26:661–667.
14. Yang FY, Teng MC, Lu M, et al. Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound. *Int J Nanomedicine*. 2012;7:965–974.
15. Yang FY, Wang HE, Lin GL, Lin HH, Wong TT. Evaluation of the increase in permeability of the blood-brain barrier during tumor progression after pulsed focused ultrasound. *Int J Nanomedicine*. 2012;7:723–730.
16. Yang FY, Wong TT, Teng MC, et al. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. *J Control Release*. March 3, 2012. [Epub ahead of print.]
17. Yang F, Fu W, Chen W, Yeh W, Lin W. Quantitative evaluation of the use of microbubbles with transcranial focused ultrasound on blood-brain-barrier disruption. *Ultrasound Sonochem*. 2008;15:636–643.
18. Yang F, Fu W, Yang R, Liu H, Kang K, Lin W. Quantitative evaluation of focused ultrasound with a contrast agent on blood-brain barrier disruption. *Ultrasound Med Biol*. 2007;33:1421–1427.
19. Sharma HS, Dey PK. Influence of long-term immobilization stress on regional blood-brain barrier permeability, cerebral blood flow and 5-h level in conscious normotensive young rats. *J Neurol Sci*. 1986;72:61–76.
20. McDannold N, Vykhodtseva N, Hynynen K. Targeted disruption of the blood-brain barrier with focused ultrasound: Association with cavitation activity. *Phys Med Biol*. 2006;51:793–807.
21. Unger EC, McCreery TP, Sweitzer RH, Caldwell VE, Wu Y. Acoustically active lipospheres containing paclitaxel: A new therapeutic ultrasound contrast agent. *Invest Radiol*. 1998;33:886–892.
22. Bednarski MD, Lee JW, Callstrom MR, Li KC. In vivo target-specific delivery of macromolecular agents with mr-guided focused ultrasound. *Radiology*. 1997;204:263–268.
